Drug
Ibrutinib clinical trials
Also written Imbruvica, PCI-32765 and CRA-032765.
- studies test it
- 284
- open now
- 17
- in phase 3
- 30
- first study started
- 2009
Keep track of what changes. Save the ibrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
284 studies that test it; most in 2016 (54)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 15 |
| 2013 | 21 |
| 2014 | 22 |
| 2015 | 36 |
| 2016 | 54 |
| 2017 | 28 |
| 2018 | 29 |
| 2019 | 24 |
| 2020 | 24 |
| 2021 | 9 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 117
- Phase 2
- 178
- Phase 3
- 30
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 29
Who runs them
Industry 90 · Other 194
Janssen Research & Development, LLC (31) · Pharmacyclics LLC. (27) · National Cancer Institute (NCI) (21) · M.D. Anderson Cancer Center (20) · Dana-Farber Cancer Institute (9) · Mayo Clinic (8) · Memorial Sloan Kettering Cancer Center (8) · German CLL Study Group (5)
Often tested with
Tested in the same studies.
Rituximab (38) · Venetoclax (31) · Obinutuzumab (26) · Lenalidomide (24) · Nivolumab (9) · Prednisone (7) · Bendamustine (7) · Bortezomib (7)
Studies
Open first, then newest update. How each study uses ibrutinib is read from its arms, and is right about nine times in ten.
Testing it · 284
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04421560Written as Ibrutinib
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Ibrutinib
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Ibrutinib
- A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationPhase 1Janssen Research & Development, LLCNCT06788509Written as JNJ-54179060
- Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingPhase 2Canadian Cancer Trials GroupNCT05998642Written as Ibrutinib
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Yazeed SawalhaNCT06536049Written as Ibrutinib
- Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 AlterationsNot yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07738887Written as Ibrutinib Oral Tablet
- A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)RecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07082868Written as ibrutinib
- Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL TrialRecruitingPhase 1/2OHSU Knight Cancer InstituteNCT06357676Written as Ibrutinib
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07169565Written as Ibrutinib
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingPhase 2/3University College, LondonNCT04061512Written as Rituximab, ibrutinib
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT05694312Written as Ibrutinib 420 mg
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 2Paolo GhiaNCT04758975Written as Ibrutinib
- A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04129710Written as Ibrutinib
- A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 1/2Jeanette LundinNCT04771507Written as Ibrutinib
- A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT03980002Written as Ibrutinib and Thalidomide
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaRecruitingPhase 3Prof. Dr. M. Dreyling (co-chairman)NCT02858258Written as Ibrutinib (Induction)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01886872Written as Ibrutinib
- Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedPhase 2AbbVieNCT05105841Written as Ibrutinib
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingPhase 1/2Institut CurieNCT04446962Written as Ibrutinib
See all 284 studies that test ibrutinib →
Given in every arm · 36 — ibrutinib is usual care beside what is tested
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)RecruitingPhase 1/2Curis, Inc.NCT03328078Written as Ibrutinib
- Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain CancerRecruitingPhase 1Theodore S. JohnsonNCT05106296Written as Ibrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Ibrutinib
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04494503Written as Ibrutinib
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingPhase 2Christian Schmidt, MDNCT06482684Written as Ibrutinib
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03701282Written as Ibrutinib
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic LeukemiaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03737981Written as Ibrutinib
- Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03964090Written as Ibrutinib
- Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedPhase 1Case Comprehensive Cancer CenterNCT03535350Written as Ibrutinib
- A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingPhase 2Janssen Research & Development, LLCNCT05963074Written as Ibrutinib
- Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell LymphomaActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04802590Written as Ibrutinib 560 mg
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaActive, not recruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT04212013Written as Ibrutinib
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingPhase 2GenmabNCT05283720Written as Ibrutinib
- Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02007044Written as Ibrutinib
- Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCTerminatedPhase 2University of California, San DiegoNCT03646461Written as Ibrutinib 560mg PO daily (Imbruvica)
- Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03710772Written as Ibrutinib
- ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT02787369Written as Ibrutinib
- Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)CompletedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02315326Written as Ibrutinib
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Ibrutinib
Showing 20 of 36.
As the comparator · 10 — what is tested is compared with ibrutinib
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as Ibrutinib
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136559Written as Ibrutinib
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 3Loxo Oncology, Inc.NCT05254743Written as Ibrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Ibrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Ibrutinib
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 3Acerta Pharma BVNCT02477696Written as Ibrutinib
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedPhase 3Incyte CorporationNCT03112603Written as Ibrutinib
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedPhase 3BeiGeneNCT03734016Written as Ibrutinib
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnPhase 3Acerta Pharma BVNCT02735876Written as ibrutinib
- Combination of Ibrutinib and As2O3 in the Treatment of CLLStatus unknownPhase 3Peking University People's HospitalNCT02757040Written as ibrutinib
Codes
What other systems call ibrutinib · ClinicalTrials.gg INT005692
- MeSH (NLM) C551803ibrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1X70OSD4VXIBRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1442981Confirmed FDA, Wikidata
- Wikidata Q5984881ibrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81934IbrutinibOne source FDA
- DrugBank DB09053One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551803 | ibrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1X70OSD4VX | IBRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1442981 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5984881 | ibrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81934 | Ibrutinib | One source FDA |
| DrugBank | DB09053 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.